Entrar/Registro  
INICIO ENGLISH
 
Acta Médica Grupo Ángeles
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Acta Médica Grupo Ángeles >Año 2012, No. 4


López DE, Melgarejo HMA, Aguilar-Salinas CA
La diabetes tipo 2 y la tuberculosis en México: la confluencia de dos retos para el sistema de salud
Acta Med 2012; 10 (4)

Idioma: Español
Referencias bibliográficas: 65
Paginas: 189-195
Archivo PDF: 372.39 Kb.


Texto completo




RESUMEN

Objetivo: Revisar las consecuencias para la salud de la interacción entre la diabetes tipo 2 y la tuberculosis. Material y métodos: Se revisaron los trabajos registrados en Pubmed sobre el tema durante los 10 años más recientes. Resultados: La diabetes tipo 2 es el principal problema de salud en México. La prevalencia nacional es 14.4% en adultos mayores de 20 años. Es la causa más frecuente de incapacidad prematura, ceguera, insuficiencia renal y de amputaciones. Por otra parte, 30-40% de la población adulta mexicana está infectada con Mycobacterium tuberculosis y, por lo tanto, en riesgo de desarrollar tuberculosis por reactivación. La diabetes triplica el riesgo de desarrollar tuberculosis. La diabetes puede disminuir la eficacia de las acciones preventivas de la tuberculosis activa, ya que facilita la infección de adquisición reciente y la reactivación de las formas latentes. Conclusiones: Es necesaria la búsqueda sistemática de la diabetes en todo paciente con tuberculosis. La coexistencia de estas enfermedades puede tener un efecto indeseable en el número de casos con tales patologías y en la severidad de la infección por Mycobacterium tuberculosis.


Palabras clave: Tuberculosis, diabetes mellitus, Mycobacterium tuberculosis.


REFERENCIAS

  1. Bygbjerg IC. Double burden of noncommunicable and infectious diseases in developing countries. Science 2012; 337: 1499-501.

  2. Remais JV. Convergence of non-communicable and infectious diseases in low- and middle-income countries. Int J Epidemiol 2012 Oct 13. [Epub ahead of print].

  3. Yach D. The global burden of chronic diseases: Overcoming impediments to prevention and control. JAMA 2004; 291: 2616-2622.

  4. Pérez-Guzmán C, Vargas MH. Diabetes, aging, and tuberculosis. Lung India 2011; 28: 191-192.

  5. Pérez-Navarro LM, Fuentes-Domínguez F, Morales-Romero J, Zenteno-Cuevas R. Factors associated to pulmonary tuberculosis in patients with diabetes mellitus from Veracruz, México. Gac Med Mex 2011; 147: 219-225.

  6. Restrepo BI, Camerlin AJ, Rahbar MH, Wang W et al. Cross-sectional assessment reveals high diabetes prevalence among newly-diagnosed tuberculosis cases. Bull World Health Organ 2011; 89: 352-359.

  7. Gonzalez-Curiel I, Castañeda-Delgado J, Lopez-Lopez N, Araujo Z. Differential expression of antimicrobial peptides in active and latent tuberculosis and its relationship with diabetes mellitus. Hum Immunol 2011; 72: 656-662.

  8. Robinson KL, Ernst KC, Johnson BL, Rosales C. Health status of southern Arizona border counties: A Healthy Border 2010 midterm review. Rev Panam Salud Publica 2010; 28: 344-352.

  9. Hernandez-Pando R, Orozco H, Aguilar D. Factors that deregulate the protective immune response in tuberculosis. Arch Immunol Ther Exp (Warsz) 2009; 57: 355-367.

  10. Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G et al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Infect Dis 2008; 40: 888-93.

  11. Arce-Mendoza A, Rodriguez-de Ita J, Salinas-Carmona MC, Rosas-Taraco AG. Expression of CD64, CD206, and RAGE in adherent cells of diabetic patients infected with Mycobacterium tuberculosis. Arch Med Res 2008; 39: 306-311.

  12. Restrepo BI, Fisher-Hoch SP, Crespo JG, Whitney E et al. Type 2 diabetes and tuberculosis in a dynamic bi-national border population. Epidemiol Infect 2007; 135: 483-491.

  13. Pérez A, Brown HS 3rd, Restrepo BI. Association between tuberculosis and diabetes in the Mexican border and non-border regions of Texas. Am J Trop Med Hyg 2006; 74: 604-611.

  14. Aguilar-Salinas CA. Diabetes and tuberculosis: In the labyrinth of the subdevelopment. Rev Invest Clin 2005; 57: 82-84.

  15. Vargas MH, Furuya ME, Pérez-Guzmán C. Effect of altitude on the frequency of pulmonary tuberculosis. Int J Tuberc Lung Dis 2004; 8: 1321-1324.

  16. Garza A, Rodriguez-Lainz A, Ornelas IJ. The health of the California region bordering Mexico. J Immigr Health 2004; 6: 137-144.

  17. Ponce-De-León A, García-García ML, Garcia-Sancho MC, Gomez-Perez FJ et al. Tuberculosis and diabetes in southern Mexico. Diabetes Care 2004; 27: 1584-1590.

  18. Pérez-Guzmán C, Vargas MH, Torres-Cruz A, Pérez-Padilla JR et al. Diabetes modifies the male: female ratio in pulmonary tuberculosis. Int J Tuberc Lung Dis 2003; 7: 354-358.

  19. Pérez-Guzman C, Torres-Cruz A, Villarreal-Velarde H, Salazar-Lezama MA et al. Atypical radiological images of pulmonary tuberculosis in 192 diabetic patients: A comparative study. Int J Tuberc Lung Dis 2001; 5: 455-461.

  20. Pérez-Guzman C, Torres-Cruz A, Villarreal-Velarde H, Vargas MH. Progressive age-related changes in pulmonary tuberculosis images and the effect of diabetes. Am J Respir Crit Care Med 2000; 162: 1738-1740.

  21. Milián F, Sánchez LM, Toledo P, Ramírez C et al. Descriptive study of human and bovine tuberculosis in Querétaro, Mexico. Rev Latinoam Microbiol 2000; 42: 13-19.

  22. Chen L. The worldwide epidemiology of type 2 diabetes mellitus. Present and future perspectives. Nat Rev Endocrinol 2011; 8: 228-236.

  23. Shaw JE. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4–14.

  24. Danaei G. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31–40.

  25. Echouffo-Tcheugui JB, Dagogo-Jack S. Preventing diabetes mellitus in developing countries. Nat Rev Endocrinol 2012; 8: 557-562.

  26. Córdova-Villalobos JA. Chronic non-communicable diseases in Mexico: epidemiologic synopsis and integral prevention. Salud Publica Mex 2008; 50: 419-427.

  27. Aguilar-Salinas CA, Olaiz G, Valles V, Ríos JM et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res 2001; 42: 1298-307.

  28. Aguilar-Salinas CA, Velazquez Monroy O, Gómez-Pérez FJ et al. for the ENSA 2000 Group. Characteristics of the patients with type 2 diabetes in Mexico: results from a large population-based, nation-wide survey. Diabetes Care 2003; 26: 2021-2026.

  29. Villalpando S, Rojas R, Shamah-Levy T et al. Prevalence and distribution of type 2 diabetes mellitus type 2 in Mexican adult population. A probabilistic survey. Salud Publica Mex 2010; 52 (suppl 1): S19-S26.

  30. Villalpando S, Shamah-Levy T, Rojas R, Aguilar-Salinas CA. Trends for type 2 diabetes and other cardiovascular risk factors in Mexico from 1993-2006. Salud Publica Mex 2010; 52 (supl 1): S72-S79.

  31. Aguilar-Salinas CA, Gómez Pérez FJ, Rull JA, Villalpando S, Barquera S, Rojas R. Prevalence of dyslipidemias in the 2006 Encuesta Nacional de Salud y Nutrición. Salud Publica Mex. 2010: 52 (suppl 1) S44-S53.

  32. Gakidou E, Mallinger L, Abbott-Klafter J et al. Management of diabetes and associated cardiovascular risk factors in seven countries: A comparison of data from national health examination surveys. Bull World Health Organ 2011; 89: 172–183.

  33. Sánchez-Barriga JJ. Mortality trends from diabetes mellitus in the seven socioeconomic regions of Mexico, 2000–2007. Rev Panam Salud Publica 2010; 28: 368–375.

  34. Reynoso-Noverón N, Mehta R, Almeda-Valdes P et al. Estimated incidence of cardiovascular complications related to type 2 diabetes in Mexico using the UKPDS outcome model and a population-based survey. Cardiovasc Diabetol 2011; 10 (1): 1.

  35. Global Tuberculosis Report, 2012. Available in: http: //www.who.int/tb/publications/global_report/en/ (Revisado el 22 de octubre de 2012).

  36. Tiemersma EW. Natural history of tuberculosis: Duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: A systematic review. PLoS One 2011; 6 (4): e17601.

  37. Molina-Gamboa J, Fivera-Morales I, Ponce de León-Rosales S. Prevalence of tuberculin reactivity among healthcare workers from a mexican hospital. Infect Control Hosp Epidemiol 1994; 15: 319-320.

  38. García-García ML, Valdespino-Gómez, JL, García Sancho C, Mayar-Maya ME, Palacios-Martínez M, Balandro-Campos S et al. Underestimation of Mycobacterium tuberculosis infection in HIV infected subjects using reactivity to tuberculin and anergy panel. Int J Epidemiol 2000; 29(2): 369-375.

  39. Dirección General de Epidemiología. Panorama Epidemiológico 2000-2012. Tuber 2011; 1 (10).

  40. García-García ML, Ponce de León A, Balandro–Campos S et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med 2000; 160: 630-636.

  41. Granich RM, Balandro S, Santaella AJ, Binkin NJ, Castro KG, Marquez-Fiol A et al. Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican states, 1997. Arch Intern Med 2000; 160: 639-644.

  42. Rajalakshmi S. Yugi’s pramegam and diabetes mellitus: an analogue. Bull Indian Inst Hist Med Hyderabad 1999; 29: 83–87.

  43. Root H. The association of diabetes and tuberculosis. N Engl J Med 1934; 210: 1,78,127.

  44. Boucot KR. Tuberculosis among diabetics: the Philadelphia survey. Am Rev Tuberc 1952; 65: 1–50.

  45. Stevenson CR. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 2007; 7: 234.

  46. Jeon CY. Diabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 observational studies. PLoS Med 2008; 5(7):e152. doi: 10.1371/journal.pmed.0050152.

  47. Restrepo BI. Cross-sectional assessment reveals high diabetes prevalence among newly-diagnosed tuberculosis cases. Bull World Health Organ 2011; 89: 352–359.

  48. Dooley K. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg 2009; 80: 634–639.

  49. Alisjahbana B. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007; 45: 428–435.

  50. Dooley KE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009; 9: 737-746.

  51. Bermejo M. Tuberculin test in diabetic patients in a health center. Aten Primaria 1995; 16: 154–157.

  52. Jeon CY. Diabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 observational studies. PLoS Med 2008; 5(7):e152. doi: 10.1371/journal.pmed.0050152.

  53. Pablos-Mendez A. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997; 87: 574–579.

  54. Weaver RA. Unusual radiographic presentation of pulmonary tuberculosis in diabetic patients. Am Rev Respir Dis 1974; 109: 162–163.

  55. Marais RM. Diabetes mellitus in black and coloured tuberculosis patients. S Afr Med J 1980; 57: 483–484.

  56. Al-Tawfiq JA, Saadeh BM. Radiographic manifestations of culture-positive pulmonary tuberculosis: Cavitary or non-cavitary? Int J Tuberc Lung Dis 2009; 13: 367–370.

  57. Bacakoglu F, Basoglu OK, Cok G, Sayiner A, Ates M. Pulmonary tuberculosis in patients with diabetes mellitus. Respiration 2001; 68: 595–600.

  58. Mboussa J, Monabeka H, Kombo M, Yokolo D, Yoka-Mbio A, Yala F. Course of pulmonary tuberculosis in diabetics. Rev Pneumol Clin 2003; 59: 39–44.

  59. Wang CS, Yang CJ, Chen HC et al. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect 2009; 137: 203–310.

  60. Hendy M, Stableforth D. The effect of established diabetes mellitus on the presentation of infiltrative pulmonary tuberculosis in the immigrant Asian community of an inner city area of the United Kingdom. Br J Dis Chest 1983; 77: 87–90.

  61. Alisjahbana B, Sahiratmadja E, Nelwan EJ et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007; 45: 428–435.

  62. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg 2009; 80: 634–639.

  63. Oursler KK, Moore RD, Bishai WR, Harrington SM, Pope DS, Chaisson RE. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis 2002; 34: 752–759.

  64. Stop TB Department and Department of Chronic Diseases and Health Promotion World Health Organization and The International Union Against Tuberculosis and Lung Disease. Collaborative framework for care and control of tuberculosis and diabetes. Geneva, Switzerland: WHO Document Production Services; 2011. Available in: http://whqlibdoc.who.int/publications/2011/9789241502252_eng.pdf

  65. Sullivan T. The co-management of tuberculosis and diabetes: challenges and opportunities in the developing world. PLoS Med. 2012;9(7):e1001269. doi: 10.1371/journal.pmed.1001269.



>Revistas >Acta Médica Grupo Ángeles >Año2012, No. 4
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019